Matthias A. Hediger
University of Bern, Switzerland


David Hepworth
Department of Worldwide Medicinal Chemistry, Pfizer, Cambridge, USA

Ken-ichi Inui
Kyoto Pharmaceutical University, Japan

Bruno Stieger
University of Zürich, Switzerland

  Transcure SNF Uni Bern
Transcure SNF Uni Bern



DOWNLOAD the preliminary program, speaker list and presentation titles HERE

Session 1 will start with an overview of the SLC solute carriers by the conference organizer, Matthias Hediger. This will be followed by the keynote lecture of Prof. Kathleen M. Giacomini who will review the genetic variants of SLC solute carriers and ABC transporters and their implications in human disease and drug response.

Sessions 2 and 4 will address novel breakthroughs in the SLC transporter field as well as strategies to identify novel transport proteins as targets for effective therapies.

Session 3 will highlight chemical approaches to help study SLC membrane transport proteins. Such chemical strategies are a central focus for our conference.

Sessions 5a and 5b will highlight progress within the NCCR TransCure network in the field of membrane transport (e.g. novel structural work on ABC transporters and the biology of placental transporters).

Session 6 will focus on new progress pertaining to the structural biology of SLC transporters, highlighting the implication and importance of this knowledge in drug discovery. This will include novel insight into the structures of different SLCs as well as the cholesterol transport protein NPC1.

Session 7 will be a “double session” on “store-operation calcium channels”, another major scientific focus of this conference. Recent insight revealed that store-operated calcium channels (including STIM1, STIM2, ORAI1, ORAI2, ORAI3 and certain TRP channels) are attractive therapeutic targets for the treatment of human diseases, such as cancer and immunological disorders.

Session 8 will focus on renal membrane transporters in health and disease, focusing on their role in renal diseases and the regulation of acid-base balance.

Session 9 will review the role of transporters in the development of strategies for cancer treatment, with a special focus on amino acid transporters and the altered metabolism of cancer cells.

Session 10 will address the asymmetric tissue distribution of drugs and drug targeting strategies.

The topic of session 11 will be on SLC membrane transporters of the CNS and their roles in neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease, in depression and in autism spectrum disorders.

Of special interest will furthermore be session 12, as it will review the role of membrane transporters in our understanding and prediction of how drugs behave in our body. Specifically, this session will address their impact in ADMET, drug safety and drug-drug interactions (DDI).